ARKANSAS DEPARTMENT OF HUMAN SERVICES

Division of Medical Services
Pharmacy Program

P.O. Box 1437, Slot S415 · Little Rock, AR 72203-1437
501-683-4120 · Fax: 501-683-4124 or 1-800-424-5851

ARKANSAS MEDICAID DUR/DRC BOARD QUARTERLY DRUG UPDATE
January 18, 2023 8:30 A.M. – 12:30 P.M.
VIRTUAL ZOOM MEETING
****TENTATIVE AGENDA IS SUBJECT TO CHANGE****

I. OUTSIDE SPEAKERS

DUR/DRC Board Bylaws, Section 7.02 Outside Speakers -- Outside speakers with clinical or scientific credentials or patient experience pertinent to a product or topic that is posted on the upcoming DURDRC Board meeting agenda may request to speak on that product or topic. Requests to speak at the DUR/DRC Board meeting must be made in writing to the DUR Chairperson at least two (2) weeks before the DUR/DRC Board meeting date, and should include:

1. The speaker's name, title, relevant credentials, and organization;
2. Contact information for the speaker including address, telephone number, and email;
3. The agenda item(s) which the speaker intends to address;
4. Prepared comments; and
5. Any educational materials for Board members in advance of the meeting.

This information shall be included in information sent to Board members two (2) weeks prior to the Board meeting. Presentations or public comments given at the DUR/DRC Board meeting are limited to a total of six (6) minutes per drug, which may be shared by multiple speakers. This time limit does not include responses to any questions raised by DUR/DRC Board members during the course of the meeting.

A copy of the proposed criteria for the specific agenda item on which an individual requests to speak may be requested from the Chairperson three (3) weeks prior to the DUR/DRC Board meeting. The information will be in draft form and may be changed by the DUR/DRC Board prior to being finalized. As such, the draft criteria should not be shared with clinicians or patients.

II. UNFINISHED / OLD BUSINESS AND GENERAL ORDERS / AND PROPOSALS TO REVISE PREVIOUS CRITERIA

A. ANNOUNCEMENTS
B. APPROVAL OF THE MINUTES FROM THE PREVIOUS MEETING.
C. UPDATE ON SYSTEM EDITS, IMPLEMENTATIONS, OR FOLLOW-UP ITEMS.
   1) Follow-up items from October 19, 2022 DUR Board and November 9, 2022 DRC meetings: None
   2) Implementation information from October 19, 2022 DUR Board and November 9, 2022 DRC meetings
   3) PDL adherence
   4) PA summary
D. NEW PDL CLASS REVIEW
   1) Cephalosporins
E. PDL CLASS REVIEW WITH CRITERIA
   1) Leukotriene Receptor Antagonists
F. PROPOSED CHANGES TO EXISTING CRITERIA and EDITS, INCLUDING POINT OF SALE (POS) CRITERIA, MANUAL REVIEW PA CRITERIA, OR CLAIM EDITS:
   1) Update criteria for antimigraine agents (non-triptan)

III. NEW BUSINESS

A. PROPOSED NEW CLINICAL POINT OF SALE CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS: None
B. MANUAL REVIEW PROPOSED CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS:
   1) Vivjoa™ (oteseconazole) capsule—tabled during October 2022 DUR meeting
   2) Enspryng® (satralizumab-mwge) syringe—tabled during October 2022 DUR meeting
   3) Multiple Sclerosis Drugs
   4) Qutenza® (capsaicin) kit
   5) Lytgobi® (futibatinib) tablet
   6) Hyftor™ (sirolimus) gel
   7) Rezlidhia™ (olutasidenib) capsules—if rebate eligible at the time of meeting
C. PROPOSED NEW CLAIM EDITS (QUANTITY, DAILY DOSE, ACCUMULATION, GENDER, AGE): None
D. ProDUR REPORT UPDATE
E. RDUR REPORT UPDATE